Elutia Collects $8M Escrow from Boston Scientific Deal
Elutia has received an $8 million escrow payment tied to its BioEnvelope sale to Boston Scientific, extending the company's funding runway into 2029.
Elutia has received the full $8 million held in escrow related to its earlier sale of the BioEnvelope business to Boston Scientific, the company announced, giving it sufficient capital to operate through 2029.
The escrow release represents the final financial milestone from the BioEnvelope transaction, completing the monetary terms of that divestiture. Elutia said the infusion means the company is now fully funded for the foreseeable future, a significant operational milestone for a medical-device firm navigating a competitive market.
Read more KULR Technology Wins $1M+ Battery Orders for Defense Drone Program →
For investors and stakeholders, the funding visibility through 2029 reduces near-term capital-raise uncertainty, a factor that often weighs on smaller medical-technology companies dependent on partnership proceeds. The escrow resolution removes a financial contingency that had remained open since the Boston Scientific deal closed.
The BioEnvelope product line, which Elutia divested to Boston Scientific, was a key asset in the company's portfolio. Proceeds from that transaction, now fully realized, appear to underpin Elutia's stated multi-year runway as the company pursues its remaining business objectives.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
